Skip to main content

Search

Reset all filters
434 Result(s)
Sort by

GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Our Expectations

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
The power of our people

The power of our people

Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
International Women's Day

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
Innovation from within

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Overcoming heartworm disease for homeless pets

Overcoming heartworm disease for homeless pets

Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Risk of parasites in dogs

Risk of parasites in dogs

With our Parassess free online tool checker, you can assess the local parasite risks for your dog so you can protect them better.
Partnership canine oncology

Partnership canine oncology

The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Rahul Prasad

Rahul Prasad

Rahul J. Prasad is a Senior Consultant with our Corporate Strategy & Consulting division – a job that suits his passion for data and his love of variety.
FDA approval NexGard PLUS for dogs

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Partnering pet therapeutics

Partnering pet therapeutics

Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Siva Thotapalli

Siva Thotapalli

My career challenge at Boehringer Ingelheim by Siva Thotapalli. Read it now!